secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-11-22T23:59:59+00:00
Accession:  0001104659-24-122099
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics gets Nasdaq deficiency for equity ($707K vs $2.5M min); also faces bid-price delisting risk
--------------------------------------------------------------------------------

- Stockholders' equity of $707,000 at Sep 30, 2024 is below Nasdaq's $2.5 million minimum.
- Company has 45 days (by Jan 3, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.
- Also has outstanding minimum bid price deficiency; must close at $1.00+ for 10 consecutive days by Jan 27, 2025.
- Listing remains effective pending compliance; company evaluating options including reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924122099/0001104659-24-122099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924122099/tm2429290d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-122099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer